A pilot study evaluating serum pro-prostate-specific antigen in patients with rising PSA following radical prostatectomy

Oncology Letters

Volumn 3, Issue 4, 2012, Pages 819-824

  Sottile, Antonino ^a   Ortega, Cinzia ^a   Berruti, Alfredo ^b   Mangioni, Monica ^a   Saponaro, Sara ^a   Polo, Alessandra ^a   Prati, Veronica ^a   Muto, Giovanni ^c   Aglietta, Massimo ^a   Montemurro, Filippo ^a  

^a CANDIOLO CANCER INSTITUTE   (Italy)

^b SAN LUIGI GONZAGA HOSPITAL   (Italy)

^c S GIOVANNI BOSCO HOSPITAL   (Italy)

Author keywords

2 pro prostate specific antigen; Biochemical recurrence; Cancer metastasis; Prostate cancer

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER PATIENT; CANCER RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC IMAGING; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; POSITRON EMISSION TOMOGRAPHY; PROSTATE CANCER; PROSTATECTOMY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

EID: 84856829087     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.570     Document Type: Article

References (26)

1. Makarov DV, Loeb S, Getzenberg RH and Partin AW: Biomarkers for prostate cancer. Annu Rev Med 60: 139-151, 2009.
2. Antonarakis ES, Chen Y, Elsamanoudi SI, Brassell SA, Da Rocha MV, Eisenberger MA and McLeod DG: Long-term overall survival and metastasis-free survival for men with prostate-specific antigen-recurrent prostate cancer after prostatectomy: analysis of the Center for Prostate Disease Research National Database. BJU Int 108: 378-385, 2011.
3. Scattoni V, Roscigno M, Raber M, et al: Multiple vesico-urethral biopsies following radical prostatectomy: the predictive roles of TRUS, DRE, PSA and the pathological stage. Eur Urol 44: 407-414, 2003.
4. Kane CJ, Amling CL, Johnstone PA, et al: Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. Urology 61: 607-611, 2003.
5. Kattan MW, Wheeler TM and Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499-1507, 1999.
6. Makarov DV, Isharwal S, Sokoll LJ, et al: Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer. Clin Cancer Res 15: 7316-7321, 2009.
7. Mikolajczyk SD, Marker KM, Millar LS, et al: A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61: 6958-6963, 2001.
8. Mikolajczyk SD, Catalona WJ, Evans CL, et al: Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50: 1017-1025, 2004.
9. Sokoll LJ, Wang Y, Feng Z, et al: [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study. J Urol 180: 539-543, 2008.
10. Semjonow A, Kopke T, Eltze E, Pepping-Schefers B, Burgel H and Darte C: Pre-analytical in-vitro stability of [-2]proPSA in blood and serum. Clin Biochem 43: 926-928, 2010.
11. Catalona WJ, Bartsch G, Rittenhouse HG, et al: Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170: 2181-2185, 2003.
12. Stephan C, Kahrs AM, Cammann H, et al: A [-2]proPSA-based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases. Prostate 69: 198-207, 2009.
13. Sokoll LJ, Sanda MG, Feng Z, et al: A prospective, multicenter, National Cancer Institute Early Detection Research Network study of [-2]proPSA: improving prostate cancer detection and correlating with cancer aggressiveness. Cancer Epidemiol Biomarkers Prev 19: 1193-1200, 2010.
14. Le BV, Griffin CR, Loeb S, Carvalhal GF, Kan D, Baumann NA and Catalona WJ: [-2]Proenzyme prostate specific antigen is more accurate than total and free prostate specific antigen in differentiating prostate cancer from benign disease in a prospective prostate cancer screening study. J Urol 183: 1355-1359, 2010.
15. Catalona WJ, Sanda MG, Wei JT, et al: [-2]ProPSA in combination with PSA and free-PSA, using the Beckman Coulter access immunoassay systems improves prostate cancer detection relative to PSA and free-PSA. A multi-center prospective clinical study. J Urol 183: e717, 2010.
16. Clarke NW: What does failure after surgery or radiation mean? Eur Urol Suppl 7: 410-415, 2008.
17. Simmons MN, Stephenson AJ and Klein EA: Natural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapy. Eur Urol 51: 1175-1184, 2007.
18. Jansen FH, Roobol M, Jenster G, Schroder FH and Bangma CH: Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins. Eur Urol 55: 563-574, 2009.
19. Stenman UH, Leinonen J, Zhang WM, Finne P and Wu P: The clinical importance of free prostate-specific antigen (PSA). Curr Opin Urol 8: 393-399, 1998.
20. Catalona WJ, Smith DS, Wolfert RL, Wang TJ, Rittenhouse HG, Ratliff TL and Nadler RB: Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA 274: 1214-1220, 1995.
21. Partin AW, Catalona WJ, Southwick PC, Subong EN, Gasior GH and Chan DW: Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age. Urology 48: 55-61, 1996.
22. Finne P, Finne R, Bangma C, Hugosson J, Hakama M, Auvinen A and Stenman UH: Algorithms based on prostate-specific antigen (PSA), free PSA, digital rectal examination and prostate volume reduce false-positive PSA results in prostate cancer screening. Int J Cancer 111: 310-315, 2004.
23. Finne P, Auvinen A, Maattanen L, et al: Diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. Eur Urol 54: 362-370, 2008.
24. Lin DW, Noteboom JL, Blumenstein BA, Ellis WJ, Lange PH and Vessella RL: Serum percent free prostate-specific antigen in metastatic prostate cancer. Urology 52: 366-371, 1998.
25. Vickers AJ, Savage C, O'Brien MF and Lilja H: Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. J Clin Oncol 27: 398-403, 2009.
26. Denham JW, Steigler A, Wilcox C, et al: Time to biochemical failure and prostate-specific antigen doubling time as surrogates for prostate cancer-specific mortality: evidence from the TROG 96.01 randomised controlled trial. Lancet Oncol 9: 1058-1068, 2008.